Citations

Clear

585 citation(s) found for "Tran, Ha".

Trapezoid Avascular Necrosis
Tran, Aaron , Mousa, Abeer, Tassel, Dane C. Van

Mayo Clinic

No container title available | June 5, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1148/cases.20237017 Get It

Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.
Phillips, Ryan , Proudfoot, James A. , Liu, Yang , Feng, Felix Y. , Simko, Jeff, Pollack, Alan , Patel, Samir , Straza, Michael , Shah, Amit B. , Rodgers, Joseph P., Davicioni, Elai , Spratt, Daniel E. , Den, Robert B. , Rosenthal, Seth A. , Sartor, Oliver , Sweeney, Christopher J. , Attard, Gerhardt , Efstathiou, Jason A. , Sandler, Howard M. , Tran, Phuoc T

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 5094-5094

10.1200/jco.2023.41.16_suppl.5094 Get It

5094 Background: In prior studies, basal vs. luminal differentiation portends differential response to a) androgen suppression (AS) duration for high-risk prostate cancer (PCa) (NRG-GU-TS006) and b) docetaxel chemotherapy (CT) and AS for metastatic hormone-sensitive disease (CHAARTED). In NRG-GU-TS006, basal tumors appeared to benefit the most from longer duration of AS while those with luminal subtype did not whereas, in CHAARTED, luminal subtype had greater benefit from addition of CT. Herein, we examined basal-luminal subtyping to predict differential response to the addition of CT in the setting of high-risk PCa treated with AS and definitive radiotherapy (AS + RT) in NRG/RTOG 0521. Methods: Per pre-specified and approved NCI analysis plan (Navigator #1061), we obtained available NRG biobank biopsy specimens from patients enrolled on the NRG/RTOG 0521 phase III trial, which randomized patients to AS + RT +/- CT. The highest-grade tumors were profiled on clinical-grade whole-transcriptome arrays (Veracyte, San Diego, CA). Basal-luminal subtypes were generated using a 215-gene PCa subtyping classifier (PSC), a second generation PAM50 basal-luminal model. Treatment effects in Luminal Proliferating (LP) and non-LP subtypes were examined with Cox (for overall survival, OS, and metastasis-free survival, MFS) and Fine & Gray (for distant metastasis, DM) multivariable (MVA) models adjusted for age and trial risk stratification, as well as with restricted mean survival times (RMST). Results: Of 183 samples available for analysis (91 from control and 92 from the CT arm), 52 (28%) were classified as LP subtype. Median follow-up for OS was 9.9 years. No significant differences in clinical or pathological variables were observed between LP and non-LP subtypes. In MVA, we did not detect any significant LP subtype-by-CT treatment interaction but observed evidence of non-proportional hazards (Grambsch-Therneau test, p<0.05). In unselected patients, 5- and 10-year RMST difference between the arms was 0.9 (95% CI [-1.5, 3.4], p=0.46) and 5.7 (95% CI [-2.5, 13.9], p=0.17) months of OS. Stratifying by tumor subtype, at 5 years the RMST difference in months was 3.8 (95% CI [0.3, 7.2], p=0.03) for LP and -0.2 ([-3.4, 2.9], p=0.89) for non-LP. The RMST difference in months at 10-years was 13.7 (95% CI [-0.2, 27.5], p=0.053) for LP and 2.5 ([-7.6, 12.5], p=0.63) for non-LP. Conclusions: In pre-treatment biopsy samples from a Phase 3 trial cohort of localized high-risk men, luminal-basal subtyping of tumors demonstrated differential response to docetaxel CT. Similar to results from the CHAARTED trial of metastatic disease, LP tumors may derive greater benefit from addition of CT. Validation of these findings may enable effective earlier use of CT in men with PCa.
WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models
Conage‐Pough, Jason E. , Oh, Ju‐Hee , Mladek, Ann C. , Decker, Paul A. , Carlson, Brett L. , Zhang, Jinqiang , Liu, Lily, Mu, Zhihua, Zhong, Wei , Tran, Nhan L. , Elmquist, William F. , Agar, Nathalie Y.R. , Burgenske, Danielle M. , Decker, Paul A. , Bakken, Katrina K. , White, Forest M , Agar, Nathalie Y R , Mladek, Ann C , Tran, Nhan L , Stopka, Sylwia A. , Regan, Michael S. , Baquer, Gerard , Sun, Claire Xin , Sarkaria, Jann N. , White, Forest M.

Mayo Clinic

Neuro-Oncology Advances | May 27, 2023 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdad066 | PMID 37324218 Get It

Abstract Background Although the epidermal growth factor receptor (EGFR) is a frequent oncogenic driver in glioblastoma (GBM), efforts to therapeutically target this protein have been largely unsuccessful. The present preclinical study evaluated the novel EGFR inhibitor WSD-0922. Methods We employed flank and orthotopic patient-derived xenograft models to characterize WSD-0922 and compare its efficacy to erlotinib, a potent EGFR inhibitor that failed to provide benefit for GBM patients. We performed long-term survival studies and collected short-term tumor, plasma, and whole-brain samples from mice treated with each drug. We utilized mass spectrometry to measure drug concentrations and spatial distribution and to assess the impact of each drug on receptor activity and cellular signaling networks. Results WSD-0922 inhibited EGFR signaling as effectively as erlotinib in in vitro and in vivo models. While WSD-0922 was more CNS penetrant than erlotinib in terms of total concentration, comparable concentrations of both drugs were measured at the tumor site in orthotopic models, and the concentration of free WSD-0922 in the brain was significantly less than the concentration of free erlotinib. WSD-0922 treatment provided a clear survival advantage compared to erlotinib in the GBM39 model, with marked suppression of tumor growth and most mice surviving until the end of the study. WSD-0922 treatment preferentially inhibited phosphorylation of several proteins, including those associated with EGFR inhibitor resistance and cell metabolism. Conclusions WSD-0922 is a highly potent inhibitor of EGFR in GBM, and warrants further evaluation in clinical studies.
Spheno-Orbital Meningioma - Treatment Outcomes and Factors Influencing Recurrence
Tran, Ann Q. , Maniar, Arpita , Tooley, Andrea A. , Sisti, Michael B. , Kazim, Michael, North, Victoria S.

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | May 3, 2023 | Volume: 39 | Issue: 6 | Pages: 570-578

10.1097/iop.0000000000002403 | PMID 37133386 Get It

Purpose: To determine treatment outcomes, recurrence rates, and predictors of recurrence, to inform future therapeutic approaches for spheno-orbital meningiomas (SOM). Methods: A retrospective single-center study of SOM treated from 1990 to 2021 was conducted with comprehensive neuro-ophthalmologic follow-up at Columbia University Medical Center (CUMC). Recurrence requiring reintervention was defined clinically as worsening of visual acuity, visual field defect, or ocular motility after an initial period of stabilization or 6 months of improvement following treatment, or radiologically as either a regrowth with an increase in tumor size by 20% at the site of previous growth or a new region of tumor growth. Results: In total 46 patients met the inclusion criteria. The mean follow-up was 106 months (range 1–303). Dictated by the phenotype of the disease, patients underwent either gross- (50%), near- (17%), or subtotal resection (26%). Removal of the anterior clinoid process (ACP) was performed in 52% of patients. Nine patients (20%) required an enucleation or exenteration. Radiotherapy was employed at some point of treatment in 50% of cases. Inherited cases (24%) were referred to CUMC for treatment following 1 or more recurrences. The total recurrence rate, including inherited cases, was 54%, occurring at a mean interval of 43 months. The recurrence rate of patients treated solely at CUMC was 40%, occurring at a mean interval of 41 months. A subset of patients (32%) had 2 or more recurrences. Histopathology at the first surgery was WHO grade I (87%) and II (13%) and at the final surgery was WHO grade I (74%), II (21%), and III (4%). A subset of grade I tumors that received radiotherapy (35%) evolved to a higher grade or developed multiple recurrences without a change in histologic grade I. Grade II tumors and treatment with radiotherapy increased the odds of recurrence. Removal of the ACP and gross total resection decreased the odds of recurrence. Conclusion: Due to the routinely long interval to tumor recurrence, lifelong surveillance of patients with SOM is prudent. ACP resection and gross total resection, where possible, reduce tumor recurrence and the need for further treatment. Radiotherapy should be reserved for higher-grade meningiomas and select grade I tumors.
Survey and Evaluation of Hypertension Machine Learning Research
Toit, Clea du , Tran, Tran , Deo, Neha , Aryal, Sachin , Lip, Stefanie , Sykes, Robert , Manandhar, Ishan , Sionakidis, Aristeidis , Pattnaik, Harsha , Alsanosi, Safaa , Kassi, Maria, Lê, Ngọc Minh, Rostron, Maggie , Nichol, Sarah , Mehta, Dhruven , Tummala, Ramakumar , Reddy, Sandeep , Visweswaran, Shyam , Joe, Bina , Le, Nhu Ngoc , du Toit, Clea , Tran, Tran Quoc Bao , Pattnaik, Harsha , Alsanosi, Safaa , Rostron, Maggie , Nichol, Sarah , Aman, Alisha , Nawaz, Faisal A , Mehta, Dhruven , Tummala, Ramakumar , McCallum, Linsay , Reddy, Sandeep , Visweswaran, Shyam , Kashyap, Rahul , Joe, Bina , Padmanabhan, Sandosh , Deo, Neha N , Stevenson, Leah, Nawaz, Faisal A. , Kashyap, Rahul , Padmanabhan, Sandosh

Mayo Clinic

Journal of the American Heart Association | April 29, 2023 | Volume: 12 | Issue: 9 | Pages: No page available

10.1161/jaha.122.027896 | PMID 37119074 Get It

Background Machine learning (ML) is pervasive in all fields of research, from automating tasks to complex decision‐making. However, applications in different specialities are variable and generally limited. Like other conditions, the number of studies employing ML in hypertension research is growing rapidly. In this study, we aimed to survey hypertension research using ML, evaluate the reporting quality, and identify barriers to ML's potential to transform hypertension care. Methods and Results The Harmonious Understanding of Machine Learning Analytics Network survey questionnaire was applied to 63 hypertension‐related ML research articles published between January 2019 and September 2021. The most common research topics were blood pressure prediction (38%), hypertension (22%), cardiovascular outcomes (6%), blood pressure variability (5%), treatment response (5%), and real‐time blood pressure estimation (5%). The reporting quality of the articles was variable. Only 46% of articles described the study population or derivation cohort. Most articles (81%) reported at least 1 performance measure, but only 40% presented any measures of calibration. Compliance with ethics, patient privacy, and data security regulations were mentioned in 30 (48%) of the articles. Only 14% used geographically or temporally distinct validation data sets. Algorithmic bias was not addressed in any of the articles, with only 6 of them acknowledging risk of bias. Conclusions Recent ML research on hypertension is limited to exploratory research and has significant shortcomings in reporting quality, model validation, and algorithmic bias. Our analysis identifies areas for improvement that will help pave the way for the realization of the potential of ML in hypertension and facilitate its adoption.
A novel prostate cancer subtyping classifier based on luminal and basal phenotypes
Weiner, Adam B. , Hakansson, Alex, Zhao, Xin , Proudfoot, James A. , Ho, Julian, Zhang, JJ H., Li, Eric V. , Karnes, R. Jeffrey , Kishan, Amar U. , Reiter, Robert E. , Hamid, Anis , Ross, Ashely E., Spratt, Daniel E. , Chua, Melvin L.K. , Sweeney, Christopher J. , Schaeffer, Edward M. , Li, Eric V , Hamid, Anis A , Spratt, Daniel E , Sweeney, Christopher , Chua, Melvin L K , Liu, Yang , Den, Robert B. , Ross, Ashely E., Tran, Phuoc T , Davicioni, Elai , Attard, Gerhardt , Lotan, Tamara Levin , Zhang, JJ H.

Mayo Clinic

Cancer | April 15, 2023 | Volume: 129 | Issue: 14 | Pages: 2169-2178

10.1002/cncr.34790 | PMID 37060201 Get It

AbstractBackgroundProstate cancer (PCa) is a clinically heterogeneous disease. The creation of an expression‐based subtyping model based on prostate‐specific biological processes was sought.MethodsUnsupervised machine learning of gene expression profiles from prospectively collected primary prostate tumors (training, n = 32,000; evaluation, n = 68,547) was used to create a prostate subtyping classifier (PSC) based on basal versus luminal cell expression patterns and other gene signatures relevant to PCa biology. Subtype molecular pathways and clinical characteristics were explored in five other clinical cohorts.ResultsClustering derived four subtypes: luminal differentiated (LD), luminal proliferating (LP), basal immune (BI), and basal neuroendocrine (BN). LP and LD tumors both had higher androgen receptor activity. LP tumors also had a higher expression of cell proliferation genes, MYC activity, and characteristics of homologous recombination deficiency. BI tumors possessed significant interferon γactivity and immune infiltration on immunohistochemistry. BN tumors were characterized by lower androgen receptor activity expression, lower immune infiltration, and enrichment with neuroendocrine expression patterns. Patients with LD tumors had less aggressive tumor characteristics and the longest time to metastasis after surgery. Only patients with BI tumors derived benefit from radiotherapy after surgery in terms of time to metastasis (hazard ratio [HR], 0.09; 95% CI, 0.01–0.71; n = 855). In a phase 3 trial that randomized patients with metastatic PCa to androgen deprivation with or without docetaxel (n = 108), only patients with LP tumors derived survival benefit from docetaxel (HR, 0.21; 95% CI, 0.09–0.51).ConclusionsWith the use of expression profiles from over 100,000 tumors, a PSC was developed that identified four subtypes with distinct biological and clinical features.Plain language summary Prostate cancer can behave in an indolent or aggressive manner and vary in how it responds to certain treatments. To differentiate prostate cancer on the basis of biological features, we developed a novel RNA signature by using data from over 100,000 prostate tumors—the largest data set of its kind. This signature can inform patients and physicians on tumor aggressiveness and susceptibilities to treatments to help personalize cancer management.
Racial Disparities in Treatment Initiation and Outcomes of Chronic Hepatitis B Virus Infection in North America
Khalili, Mandana , Leonard, Kelsey R., Roberts, Lewis R. , Sterling, Richard K. , Belle, Steven H., Lau, Daryl , Chung, Raymond , Bisceglie, Adrian M. Di , Lisker‐Melman, Mauricio , Juan, Joshua, Yim, Colina, Lee, William M. , Murakam, Carol S., Perrillo, Robert, Do, Son , Han, Steven‐Huy B. , Tran, Tram T. , Cooper, Stewart , Tsai, Naoky, Younoszai, Barak, Fried, Michael, Darling, Jama M., Carithers, Robert C., Shuhart, Margaret C., Wang, Chia C. , Luketic, Velimir A. , Hoofnagle, Jay H., Doo, Edward , Park, Jang‐June , Roberts, Lewis R , Khalili, Mandana , Ghany, Marc G. , Hassan, Mohamed Ahmed Salih , Lok, Anna S. , Janssen, Harry L.A. , Wong, David , Feld, Jordan J. , Terrault, Norah A. , Fontana, Robert J. , Muir, Andrew Joseph , Evon, Donna M. , Kowdley, Kris V. , Liang, T. Jake , Chang, Kyong‐Mi , Wahed, Abdus S. , King, Wendy C. , Kleiner, David Erwin

Mayo Clinic

JAMA Network Open | April 10, 2023 | Volume: 6 | Issue: 4 | Pages: e237018

10.1001/jamanetworkopen.2023.7018 | PMID 37036707 Get It

ImportanceDisparities in treatment initiation may affect outcomes, but data on racially diverse populations with chronic hepatitis B virus (HBV) infection are limited.ObjectiveTo examine whether HBV treatment initiation and outcomes differ among racial groups.Design, Setting, and ParticipantsFrom January 14, 2011, to January 28, 2018, hepatitis B surface antigen—positive adults (age ≥18 years) not receiving anti-HBV therapy were enrolled and followed up at weeks 12, 24, and every 24 weeks thereafter in a multicenter longitudinal cohort study (Hepatitis B Research Network [HBRN] adult cohort study) conducted in North America. The last study visit and data collection were completed January 28, 2019. Data were analyzed from August 27, 2021, to August 25, 2022. All HBRN participants were included unless they had acute HBV, HIV, hepatitis C or D, less than 24-weeks of follow-up after enrollment, initiated treatment at or immediately after enrollment, or had unknown race.ExposuresParticipants had clinical and laboratory assessments and could receive anti-HBV treatment after enrollment.Main Outcomes and MeasuresHepatitis B virus treatment initiation and major adverse liver outcomes (hepatic decompensation, hepatocellular carcinoma, liver transplant, and death).ResultsOf 1550 participants, 193 (12%) were African American or Black, 1157 (75%) were Asian, 157 (10%) were White, and 43 (3%) were other races; 789 (51%) were women, and the median age was 41.2 (IQR, 32.9-51.6) years. Sociodemographic and virologic parameters differed between groups. During 5727 person-years of follow-up, 504 participants initiated treatment, with incidences of 4.8 per 100 person-years in African American or Black individuals, 9.9 per 100 person-years in Asian individuals, 6.6 per 100 person-years in White individuals, and 7.9 per 100 person-years in those of other races (P &amp;lt; .001). A lower proportion (14%) of African American or Black participants met treatment criteria compared with Asian (22%) and White (27%) individuals (P = .01). The cumulative probabilities of treatment initiation after meeting the criteria were not significantly different among racial groups (African American or Black, 0.45; Asian, 0.38; White, 0.40 at 48 weeks and African American or Black, 0.45; Asian, 0.51; White, 0.51 at 72 weeks; P = .68). The incidence of major adverse liver outcomes was 0.1 per 100 person-years and did not differ by race.Conclusions and RelevanceIn this observational study of chronic HBV, African American or Black participants were less likely than individuals of other races to meet treatment criteria, but among those who did, HBV treatment receipt did not differ significantly by race or socioeconomic factors. Not all eligible participants initiated treatment, but adverse liver outcomes were rare. These findings may not be generalizable to patients with chronic HBV receiving care in other settings.
Mechanism of KMT5B haploinsufficiency in neurodevelopment in humans and mice
Sheppard, Sarah E. , Bryant, Laura , Wickramasekara, Rochelle N. , Vaccaro, Courtney, Robertson, Brynn, Hallgren, Jodi , Hulen, Jason, Watson, Cynthia J., Faùndes, Víctor , Duffourd, Yannis , Simon, M. Celeste , Cruz, Xavier de la , Padilla, Natàlia , Flores‐Méndez, Marco , Akizu, Naiara, Smiler, Jacqueline , Silva, Renata Pellegrino da, March, Michael , Diaz‐Rosado, Abdias , Barcelos, Isabella Peixoto de , Choa, Zhao Xiang, Dubourg, Christèle , Journel, Hubert, Démurger, Florence , Mulhern, Maureen , Akman, Cigdem I. , Lippa, Natalie , Baldridge, Dustin , Haeringen, Arie van , Snoeck-Streef, Irina, Chow, Penny , Hing, Anne , Graham, John M. , Faivre, Laurence , Shen, Wei , Mao, Rong , Palumbos, Janice C. , Viskochil, David , Gahl, William A. , Hauser, Natalie , Miller, Rebecca L. , Maffeo, Jessica, Afenjar, Alexandra , Doummar, Diane , Keren, Boris , Macklin‐Mantia, Sarah K. , Meerschaut, Ilse , Zweier, Christiane , Brewer, Carole, Saggar, Anand, Smeland, Marie Falkenberg , Kumar, Ajith , Elmslie, Frances , Deshpande, Charu, Nizon, Mathilde , Ierland, Yvette van , Wilke, Martina , Slegtenhorst, Marjon van, Koudijs, Suzanne M., Chen, Jin Yun, Dredge, David, Pier, Danielle B. , Wortmann, Saskia B. , Kamsteeg, Erik‐Jan , Koch, Johannes , Haynes, Devon , Pollack, Lynda, Titheradge, Hannah , Ranguin, Kara , Denommé‐Pichon, Anne‐Sophie , Weber, Sacha , Fuente, Rubén Pérez de la , Pozo, Jaime Sánchez del, Rosales, José Miguel Lezana , Joset, Pascal , Steindl, Katharina , Mei, Davide , Lespinasse, James, Philippe, Christophe , Dauriat, Benjamin, Raymond, Laure , Cueto‐González, Anna M. , Mignot, Cyril , Grotto, Sarah, Renaldo, Florence , Drivas, Theodore G. , Hennessy, Laura , Parenti, Ilaria , Kaiser, Frank J., Kuechler, Alma, Busk, Øyvind L. , Islam, Lily, Siedlik, Jacob A. , Henderson, Lindsay B. , Juusola, Jane, Person, Richard, Schnur, Rhonda E. , Vitobello, Antonio , Banka, Siddharth , Bhoj, Elizabeth , Stessman, Holly A.F. , Lee, Pearl , Simon, M Celeste , de la Cruz, Xavier , Padilla, Natália , Flores-Mendez, Marco , Akizu, Naiara , Smiler, Jacqueline , Li, Dong , March, Michael , Peixoto de Barcelos, Isabella , Choa, Zhao Xiang , Lim, Chin Yan , Dubourg, Christèle , Mulhern, Maureen , Lippa, Natalie , Andrews, Marisa , Baldridge, Dustin , Constantino, John , Chow, Penny , Faivre, Laurence , Shen, Wei , Palumbos, Janice , Gahl, William , Tifft, Cynthia , Macnamara, Ellen , Keren, Boris , Macklin, Sarah , Meerschaut, Ilse , Callewaert, Bert , Reis, André , Smeland, Marie F , Kumar, Ajith , Elmslie, Frances , Deshpande, Charu , van Ierland, Yvette , Wilke, Martina , Koudijs, Suzanne , Pier, Danielle , Wortmann, Saskia , Kamsteeg, Erik-Jan , Haynes, Devon , Titheradge, Hannah , Ranguin, Kara , Denommé-Pichon, Anne-Sophie , Weber, Sacha , Pérez de la Fuente, Rubén , Lezana Rosales, Jose Miguel , Steindl, Katharina , Rauch, Anita , Mei, Davide , Mari, Francesco , Guerrini, Renzo , Tran Mau-Them, Frederic , Moutton, Sébastien , Cueto-González, Anna M , Drivas, Theodore G , Parenti, Ilaria , Busk, Øyvind L , Siedlik, Jacob A , Vitobello, Antonio , Banka, Siddharth , Bhoj, Elizabeth J , Stessman, Holly A F , Sheppard, Sarah E; https://orcid.org/0000-0003-3480-8123, Bryant, Laura; https://orcid.org/0000-0001-8483-8940, Wickramasekara, Rochelle N; https://orcid.org/0000-0003-3090-9357, Lee, Pearl; https://orcid.org/0000-0002-1274-2891, Simon, M Celeste; https://orcid.org/0000-0001-9106-447X, Padilla, Natália; https://orcid.org/0000-0002-7872-2279, Akizu, Naiara; https://orcid.org/0000-0001-9222-6960, Li, Dong; https://orcid.org/0000-0002-2265-6727, March, Michael; https://orcid.org/0000-0001-9173-6862, Barcelos, Isabella Peixoto; https://orcid.org/0000-0002-3843-4520 de, Choa, Zhao Xiang; https://orcid.org/0000-0002-1838-7931, Lim, Chin Yan; https://orcid.org/0000-0002-1585-002X, Mulhern, Maureen; https://orcid.org/0000-0001-8642-4741, Joset, Pascal; https://orcid.org/0000-0002-4349-9951, Steindl, Katharina; https://orcid.org/0000-0002-4425-3072, Rauch, Anita , al, et

Mayo Clinic

Science Advances | April 10, 2023 | Volume: 9 | Issue: 10 | Pages: No page available

10.1126/sciadv.ade1463 | PMID 36897941 Get It

Pathogenic variants in KMT5B , a lysine methyltransferase, are associated with global developmental delay, macrocephaly, autism, and congenital anomalies (OMIM # 617788). Given the relatively recent discovery of this disorder, it has not been fully characterized. Deep phenotyping of the largest ( n = 43) patient cohort to date identified that hypotonia and congenital heart defects are prominent features that were previously not associated with this syndrome. Both missense variants and putative loss-of-function variants resulted in slow growth in patient-derived cell lines. KMT5B homozygous knockout mice were smaller in size than their wild-type littermates but did not have significantly smaller brains, suggesting relative macrocephaly, also noted as a prominent clinical feature. RNA sequencing of patient lymphoblasts and Kmt5b haploinsufficient mouse brains identified differentially expressed pathways associated with nervous system development and function including axon guidance signaling. Overall, we identified additional pathogenic variants and clinical features in KMT5B -related neurodevelopmental disorder and provide insights into the molecular mechanisms of the disorder using multiple model systems.
Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium
Tran, Benjamin V. , Moris, Dimitrios , Markovic, Daniela , Zaribafzadeh, Hamed , Lai, Quirino , Florman, Sander , Tabrizian, Parissa , Haydel, Brandy , Ruiz, Richard M., Klintmalm, Göran B. , Lee, David D. , Verna, Elizabeth C. , Halazun, Karim J. , Tevar, Amit D. , Humar, Abhinav , Chapman, William C. , Vachharajani, Neeta , Aucejo, Federico , Lerut, Jan , Nguyen, Mindie H. , Viveiros, André , Schaefer, Benedikt , Hoppe‐Lotichius, Maria , Nydam, Trevor L. , Markmann, James F. , Mobley, Constance M. , Ghobrial, R. Mark , Langnas, Alan N. , Carney, Carol A., Berumen, Jennifer , Sudan, Debra L. , Hong, Johnny C. , Rana, Abbas , Jones, Christopher M. , Fishbein, Thomas , Busuttil, Ronald W. , Barbas, Andrew S. , Lai, Quirino , Florman, Sander S , Tabrizian, Parissa , Haydel, Brandy , Klintmalm, Goran , Lee, David D , Taner, Burcin , Hoteit, Maarouf , Levine, Matthew H , Cillo, Umberto , Verna, Elizabeth C , Halazun, Karim J , Tevar, Amit D , Humar, Abhinav , Chapman, William C , Vachharajani, Neeta , Ciccarelli, Olga , Nguyen, Mindie H , Melcher, Marc L , Viveiros, Andre , Schaefer, Benedikt , Hoppe-Lotichius, Maria , Mittler, Jens , Markmann, James F , Rossi, Massimo , Mobley, Constance , Ghobrial, Mark , Schnickel, Gabriel T , Sudan, Debra L , Hong, Johnny C , Rana, Abbas , Jones, Christopher M , Busuttil, Ronald W , Barbas, Andrew S , Agopian, Vatche G , Moris, Dimitrios , Henao, Ricardo , Ruiz, Richard , Taner, C. Burcin , Vitale, Alessandro , Melcher, Marc L. , Carney, Carol A., Agopian, Vatche G.

Mayo Clinic

Liver Transplantation | April 7, 2023 | Volume: 29 | Issue: 7 | Pages: 683-697

10.1097/lvt.0000000000000145 | PMID 37029083 Get It

HCC recurrence following liver transplantation (LT) is highly morbid and occurs despite strict patient selection criteria. Individualized prediction of post-LT HCC recurrence risk remains an important need. Clinico-radiologic and pathologic data of 4981 patients with HCC undergoing LT from the US Multicenter HCC Transplant Consortium (UMHTC) were analyzed to develop a REcurrent Liver cAncer Prediction ScorE (RELAPSE). Multivariable Fine and Gray competing risk analysis and machine learning algorithms (Random Survival Forest and Classification and Regression Tree models) identified variables to model HCC recurrence. RELAPSE was externally validated in 1160 HCC LT recipients from the European Hepatocellular Cancer Liver Transplant study group. Of 4981 UMHTC patients with HCC undergoing LT, 71.9% were within Milan criteria, 16.1% were initially beyond Milan criteria with 9.4% downstaged before LT, and 12.0% had incidental HCC on explant pathology. Overall and recurrence-free survival at 1, 3, and 5 years was 89.7%, 78.6%, and 69.8% and 86.8%, 74.9%, and 66.7%, respectively, with a 5-year incidence of HCC recurrence of 12.5% (median 16 months) and non-HCC mortality of 20.8%. A multivariable model identified maximum alpha-fetoprotein (HR = 1.35 per-log SD, 95% CI,1.22–1.50, p < 0.001), neutrophil-lymphocyte ratio (HR = 1.16 per-log SD, 95% CI,1.04–1.28, p < 0.006), pathologic maximum tumor diameter (HR = 1.53 per-log SD, 95% CI, 1.35–1.73, p < 0.001), microvascular (HR = 2.37, 95%–CI, 1.87–2.99, p < 0.001) and macrovascular (HR = 3.38, 95% CI, 2.41–4.75, p < 0.001) invasion, and tumor differentiation (moderate HR = 1.75, 95% CI, 1.29–2.37, p < 0.001; poor HR = 2.62, 95% CI, 1.54–3.32, p < 0.001) as independent variables predicting post-LT HCC recurrence (C-statistic = 0.78). Machine learning algorithms incorporating additional covariates improved prediction of recurrence (Random Survival Forest C-statistic = 0.81). Despite significant differences in European Hepatocellular Cancer Liver Transplant recipient radiologic, treatment, and pathologic characteristics, external validation of RELAPSE demonstrated consistent 2- and 5-year recurrence risk discrimination (AUCs 0.77 and 0.75, respectively). We developed and externally validated a RELAPSE score that accurately discriminates post-LT HCC recurrence risk and may allow for individualized post-LT surveillance, immunosuppression modification, and selection of high-risk patients for adjuvant therapies.
Abstract 5621: Multi-parametric MRI maps regional heterogeneity of high grade glioma phenotypes
Flick, Matthew , Weiskittel, Taylor M. , Meng-Lin, Kevin, Blomquist, Mylan, Wang, Luija, Sereduk, Christopher, León, Gustavo De , Nespodzany, Ashley , Urcuyo, Javier , Gonzalez, Ashlynn, Singleton, Kyle , Anil, Aliya , Simmineh, Natenael, Lewis, Erika , Patel, Reyna A., Wang, Panwen , Eschbacher, Jennifer , Smith, Kris A. , Bendok, Bernard R. , Zimmerman, Richard S. , Krishna, Chandan , Patra, Devi Prasad, Lyons, Mark , Neal, Matthew T. , Donev, Kliment , Mrugała, Maciej M. , Porter, Alyx B. , Beeman, Scott C. , Lasorella, Anna , Quarles, C. Chad , Tran, Nhan L. , Hu, Leland , Tran, Nhan L , D’Angelo, Fulvio , Caruso, Francesca Pia , Ensign, Shannon P. Fortin , Sereduk, Chris , Leon, Gustavo De, Curtin, Lee , Noviello, Teresa , Wang, Junwen , Hawkins‐Daarud, Andrea , Jackson, Pamela , Nakaji, Peter , Patel, Naresh P. , Zhou, Yuxiang , Baxter, Leslie C. , Plaisier, Christopher L. , Li, Jing , Li, Hu, Swanson, Kristin R , Ceccarelli, Michele , Iavarone, Antonio

Mayo Clinic

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 5621-5621

10.1158/1538-7445.am2023-5621 Get It

Abstract High grade glioma (HGG) represents a group of devastating diseases with dismal prognosis. Surgical resection of the contrast enhancing (CE) region of HGG remains the mainstay of treatment, but recurrence inevitably arises from the unresected non-contrast enhancing (NE) region, surgically inaccessible due to cancer cell invasion into healthy brain tissue. Due to its critical role in recurrence, understanding of the NE region is central to the improvement of clinical outcomes. We reveal the biological characteristics of this region through image localized multi-regional sampling. We linked microenvironmental characteristics measured by multi-parametric MRI to genomic mutations and transcriptional phenotypes using mixed effect modeling which allowed us to control for individualized patient effects. We first confirmed that T2 is a significant indicator of IDH mutation status in the NE region, being the first description of such a relationship in a HGG cohort. We found the combination of EGFR amplification and CDKN2A homozygous loss was associated with a significantly lower mean diffusivity (MD) compared to double wild type tumors in the NE region, indicating the presence of greater cellular packing and proliferation in EGFR amplification/CDKN2A loss regions. Finally, using single cell pathway based tumor classifications, we showed that nK2, a DSC-MRI metric representing cell size heterogeneity, correlated positively with neuronal signature and negatively with glycolytic/plurimetabolic signature within the NE tumor, indicating that glycolytic/plurimetobolic tumors possessed a high amount of cell size heterogeneity compared to neuronal samples. This hypothesis was supported using digital reference object (DRO) modeling which confirmed that cell size and heterogeneity drove the differential nK2 signal between neuronal and glycolytic/plurimetabolic samples. We identified immune cell infiltrate as one possible mechanism of increased cell size heterogeneity using transcriptomic signature analysis which found more immune cell signatures within glycolytic/plurimetobolic tumors compared to neuronal. Collectively this study demonstrates the central role of multi-parametric MRI as a non-invasive measure of tumor biology and a tool for understanding the clinically critical NE region which can then inform new therapies targeting this region of HGG recurrence. Citation Format: Matthew Flick, Taylor Weiskittel, Kevin Meng-Lin, Fulvio D'Angelo, Francesca Caruso, Shannon Ensign, Mylan Blomquist, Luija Wang, Christopher Sereduk, Gustavo De Leon, Ashley Nespodzany, Javier Urcuyo, Ashlynn Gonzalez, Lee Curtin, Kyle Singleton, Aliya Anil, Natenael Simmineh, Erika Lewis, Teresa Noviello, Reyna Patel, Panwen Wang, Junwen Wang, Jennifer Eschbacher, Andrea Hawkins-Daarud, Pamela Jackson, Kris Smith, Peter Nakaji, Bernard Bendok, Richard Zimmerman, Chandan Krishna, Devi Patra, Naresh Patel, Mark Lyons, Matthew Neal, Kliment Donev, Maciej Mrugala, Alyx Porter, Scott Beeman, Yuxiang Zhou, Leslie Baxter, Christopher Plaisier, Jing Li, Hu Li, Anna Lasorella, Chad Quarles, Kristin Swanson, Michele Ceccarelli, Antonio Iavarone, Nhan Tran, Leland Hu. Multi-parametric MRI maps regional heterogeneity of high grade glioma phenotypes. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5621.